Clinical trial
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
NCT02369016 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
- Lead sponsor
- Bayer
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 22, 2015
- Completion date
- October 26, 2022
- Enrollment
- 25 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.